Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Jefferies Group decreased their FY2020 earnings estimates for Neurocrine Biosciences in a research report issued to clients and investors on Tuesday. Jefferies Group analyst B. Amin now expects that the firm will post earnings per share of $1.85 for the year, down from their previous estimate of $2.13. Jefferies Group currently has a “Buy” rating and a $56.00 target price on the stock. Jefferies Group also issued estimates for Neurocrine Biosciences’ FY2021 earnings at $2.92 EPS.

Several other research firms have also recently weighed in on NBIX. Piper Jaffray Companies restated a “buy” rating and issued a $96.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, January 18th. Oppenheimer Holdings, Inc. upgraded shares of Neurocrine Biosciences from a “market perform” rating to an “outperform” rating and set a $55.00 price objective on the stock in a research report on Friday, January 27th. They noted that the move was a valuation call. Robert W. Baird reaffirmed an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday. Citigroup Inc. assumed coverage on Neurocrine Biosciences in a research note on Tuesday, November 22nd. They issued a “market perform” rating and a $55.00 target price for the company. They noted that the move was a valuation call. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Neurocrine Biosciences in a research note on Wednesday, January 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $67.23.

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

“Neurocrine Biosciences, Inc. (NBIX) to Post FY2020 Earnings of $1.85 Per Share, Jefferies Group Forecasts” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this story can be read at http://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-to-post-fy2020-earnings-of-1-85-per-share-jefferies-group-forecasts/1120801.html.

Neurocrine Biosciences (NASDAQ:NBIX) traded up 1.65% on Thursday, reaching $43.15. 926,588 shares of the company’s stock traded hands. The firm’s 50-day moving average is $41.58 and its 200 day moving average is $46.19. Neurocrine Biosciences has a 12 month low of $32.18 and a 12 month high of $55.15. The firm’s market cap is $3.75 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, February 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.05. During the same quarter in the prior year, the business posted ($0.34) EPS.

In other news, CEO Kevin Charles Gorman sold 3,750 shares of the stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $43.28, for a total transaction of $162,300.00. Following the completion of the sale, the chief executive officer now owns 240,927 shares of the company’s stock, valued at $10,427,320.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director William H. Rastetter sold 10,750 shares of the stock in a transaction that occurred on Wednesday, February 1st. The shares were sold at an average price of $42.28, for a total value of $454,510.00. Following the sale, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $1,057,000. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,816 shares of company stock valued at $1,387,036. Insiders own 4.80% of the company’s stock.

“Neurocrine Biosciences, Inc. (NBIX) to Post FY2020 Earnings of $1.85 Per Share, Jefferies Group Forecasts” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this story can be read at http://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-to-post-fy2020-earnings-of-1-85-per-share-jefferies-group-forecasts/1120801.html.

Several hedge funds have recently added to or reduced their stakes in NBIX. First Mercantile Trust Co. raised its stake in Neurocrine Biosciences by 94.9% in the third quarter. First Mercantile Trust Co. now owns 3,897 shares of the company’s stock worth $197,000 after buying an additional 1,897 shares during the period. Opus Point Partners Management LLC bought a new stake in Neurocrine Biosciences during the third quarter worth $206,000. Two Sigma Securities LLC bought a new stake in Neurocrine Biosciences during the third quarter worth $212,000. Fox Run Management L.L.C. bought a new stake in Neurocrine Biosciences during the third quarter worth $218,000. Finally, SECOR Capital Advisors LP bought a new stake in Neurocrine Biosciences during the third quarter worth $260,000. 97.60% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.